Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,31
KB-0,18
PKN99,8399,94-0,54
Msft516,53516,63-1,73
Nokia5,8025,95-4,35
IBM306,19306,32-1,21
Mercedes-Benz Group AG56,1456,16-0,39
PFE24,5524,561,09
31.10.2025 19:37:48
Indexy online
AD Index online
select
AD Index online
 

  • 31.10.2025 17:29:21
Spineguard (Paris)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
0,107 -1,83 0,00 27 683
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 31.10.2025
Popis společnosti
Obecné informace
Název společnostiSpineguard SA
TickerALSGD
Kmenové akcie:Ordinary Shares
RICALSGD.PA
ISINFR0011464452
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky30.09.2025
Počet zaměstnanců k 30.06.2025 15
Akcie v oběhu k 30.06.2025 64 561 471
MěnaEUR
Kontaktní informace
Ulice10, Cours Louis Lumiere
MěstoVINCENNES
PSČ94300
ZeměFrance
Kontatní osobaAnne-Charlotte Millard
Funkce kontaktní osobyChief Financial Officer
Telefon33 145 184 519
Fax33145184520
Kontatní telefon330 145 184 519

Business Summary: SpineGuard SA is a France-based company that engages in the design and production of medical instruments used for spinal surgeries. The Company involves with the DSG (Dynamic Surgical Guidance) technology that concentrates on the placement of bone implants for the benefit of patients, surgeons, hospital staff, and healthcare systems. The DSG digital technology platform is a real-time surgical guidance work based on the measurement of local electrical conductivity of tissues without X-rays that includes PediGuard devices, the manual instruments capable of alerting surgeons in real time to potential pedicle or vertebral breaches. The technology is also implemented for the surgical robots to improve the safety, accuracy and autonomy.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Spineguard SA revenues decreased 13% to EUR2.1M. Net loss decreased 32% to EUR1.1M. Revenues reflect United States (Country) segment decrease of 18% to EUR1.4M, World ex-United States (Region) segment decrease of 4% to EUR769K. Lower net loss reflects Labor & Related Expenses in SGA decrease of 44% to EUR474K (expense), Research and Development Expense - Other decrease of 71% to EUR113K (expense).
Odvětvová klasifikace
TRBC2009Medical Equipment / Supplies / Distribution
TRBC2012Medical Equipment
MGINDUSTRYMedical Equipment & Supplies
MGSECTORHealthcare
NAICSSurgical and Medical Instrument Manufacturing
NAICS2007Surgical & Medical Instrument Mfg
NAICS1997Surgical and Medical Instrument Manufacturing
SICSurgical And Medical Instruments



  • Poslední aktualizace: 31.10.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Chief Executive Officer, Co-Founder, Member of the Management BoardPierre Jerome-14.02.2020
Deputy Chief Executive Officer, Co-Founder, Member of the Management Board, DirectorStephane Bette-14.02.202027.03.2009
Chief Financial OfficerAnne-Charlotte Millard-31.12.2024
General Manager, USASteve Mcadoo-
Vice President - International Sales & Global MarketingPatricia Lempereur-
Director - R&DThibault Chandanson-
Director - Quality and Regulatory AffairsYannis Zoughailech-